NASDAQ:EGRXEagle Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eagle Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $50.83 -1.09 (-2.10 %) (As of 05/29/2020 03:59 PM ET) Add Compare Share Today's Range$49.26Now: $50.83▼$51.6550-Day Range$47.39MA: $51.79▼$55.0252-Week Range$33.80Now: $50.83▼$64.94Volume15,198 shsAverage Volume138,692 shsMarket Capitalization$695.86 millionP/E Ratio299.02Dividend YieldN/ABeta1.02 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingEagle Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.50, Eagle Pharmaceuticals has a potential upside of 4.6% from its current price of $50.18.Amount of Analyst CoverageEagle Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesEagle Pharmaceuticals has received 389 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEagle Pharmaceuticals has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentEagle Pharmaceuticals has received 58.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote “Outperform” if you believe EGRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEagle Pharmaceuticals does not currently pay a dividend.Dividend GrowthEagle Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 31.70% of the stock of Eagle Pharmaceuticals is held by insiders.Percentage Held by Institutions96.02% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eagle Pharmaceuticals are expected to decrease by -53.06% in the coming year, from $0.98 to $0.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eagle Pharmaceuticals is 295.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Eagle Pharmaceuticals is 295.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.06.Price to Book Value per Share RatioEagle Pharmaceuticals has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.03 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EGRX Previous Symbol CUSIPN/A CIK827871 Webwww.eagleus.com Phone201-326-5300Debt Debt-to-Equity Ratio0.17 Current Ratio1.89 Quick Ratio1.83Price-To-Earnings Trailing P/E Ratio299.02 Forward P/E Ratio51.87 P/E GrowthN/A Sales & Book Value Annual Sales$195.89 million Price / Sales3.55 Cash Flow$1.72 per share Price / Cash Flow29.63 Book Value$13.29 per share Price / Book3.82Profitability EPS (Most Recent Fiscal Year)$1.38 Net Income$14.31 million Net Margins1.29% Return on Equity8.11% Return on Assets5.07%Miscellaneous Employees96 Outstanding Shares13,690,000Market Cap$695.86 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:EGRX Rates by TradingView Receive EGRX News and Ratings via Email Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions How has Eagle Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EGRX stock has increased by 28.4% and is now trading at $50.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eagle Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eagle Pharmaceuticals. When is Eagle Pharmaceuticals' next earnings date? Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eagle Pharmaceuticals. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.62. The specialty pharmaceutical company earned $46.02 million during the quarter, compared to analyst estimates of $47.76 million. Eagle Pharmaceuticals had a net margin of 1.29% and a return on equity of 8.11%. View Eagle Pharmaceuticals' earnings history. What price target have analysts set for EGRX? 2 equities research analysts have issued 12 month target prices for Eagle Pharmaceuticals' shares. Their forecasts range from $46.00 to $59.00. On average, they expect Eagle Pharmaceuticals' share price to reach $52.50 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price. View analysts' price targets for Eagle Pharmaceuticals. Has Eagle Pharmaceuticals been receiving favorable news coverage? Media coverage about EGRX stock has trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutEagle Pharmaceuticals. Who are some of Eagle Pharmaceuticals' key competitors? Some companies that are related to Eagle Pharmaceuticals include Uniqure (QURE), Arena Pharmaceuticals (ARNA), Axsome Therapeutics (AXSM), HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Insmed (INSM), Apellis Pharmaceuticals (APLS), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB) and TG Therapeutics (TGTX). View all competitors. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Clovis Oncology (CLVS), Horizon Therapeutics (HZNP) and Neurocrine Biosciences (NBIX). Who are Eagle Pharmaceuticals' key executives? Eagle Pharmaceuticals' management team includes the following people: Mr. Scott L. Tarriff, CEO & Director (Age 59)Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)Mr. Pete A. Meyers, Chief Financial Officer (Age 49)Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39) What is Eagle Pharmaceuticals' stock symbol? Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX." Who are Eagle Pharmaceuticals' major shareholders? Eagle Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (12.86%), BlackRock Inc. (12.22%), Park West Asset Management LLC (9.02%), State Street Corp (4.57%), Invesco Ltd. (2.37%) and Tang Capital Management LLC (1.87%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View institutional ownership trends for Eagle Pharmaceuticals. Which institutional investors are selling Eagle Pharmaceuticals stock? EGRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Janus Henderson Group PLC, AJO LP, Morgan Stanley, Morgan Stanley, Squarepoint Ops LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Eagle Pharmaceuticals. Which institutional investors are buying Eagle Pharmaceuticals stock? EGRX stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Schroder Investment Management Group, Matarin Capital Management LLC, Aviva PLC, Acadian Asset Management LLC, Park West Asset Management LLC, Pictet Asset Management Ltd., and Engineers Gate Manager LP. View insider buying and selling activity for Eagle Pharmaceuticals. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eagle Pharmaceuticals' stock price today? One share of EGRX stock can currently be purchased for approximately $50.18. How big of a company is Eagle Pharmaceuticals? Eagle Pharmaceuticals has a market capitalization of $686.96 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe. What is Eagle Pharmaceuticals' official website? The official website for Eagle Pharmaceuticals is www.eagleus.com. How can I contact Eagle Pharmaceuticals? Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
